Safety and immunogenicity of the Mycobacterium tuberculosis DeltalysA DeltapanCD vaccine in domestic cats infected with feline immunodeficiency virus

Feline immunodeficiency virus (FIV)-positive and FIV-negative cats (n=4/group) received 2 x 10(6) CFU Mycobacterium tuberculosis DeltalysA DeltapanCD intramuscularly. Vaccination elicited antibody responses, albeit at lower levels in FIV-positive cats than in FIV-negative cats. Delayed-type hypersensitivity responses were minimal in both groups. No adverse reactions were found.